Mirati Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Mirati Therapeutics

08/08/2023 23:02

* Mirati Therapeutics Inc  MRTX.OQ  reported a quarterly
adjusted
loss of $3.04​​ per share for the quarter ended in June. The
mean expectation of sixteen analysts for the quarter was for a
loss of $3.17 per share.
    * Revenue rose 155.3% to $13.69 million from a year ago;
analysts
expected $13.51 million. 
    * Mirati Therapeutics Inc's reported EPS for the quarter was
a
loss of $3.04​.
    * The mean earnings estimate of analysts had risen by
about 4.8%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Mirati Therapeutics Inc shares had fallen by 22.3% this
quarter and lost 38.1% so far this year.
    * The company reported a quarterly loss of $176.91 million.
    * Wall Street's median 12-month price target for Mirati
Therapeutics Inc is $56.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 7
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 10:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -3.17          -3.04          Beat
 Mar. 31 2023      -3.55          -3.18          Beat
 Dec. 31 2022      -3.55          -3.51          Beat
 Sep. 30 2022      -3.48          -3.09          Beat